Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Lyrica (pregabalin by Year
Lyrica (pregabalin — Upjohn spin-off to Viatris Nov 2020) [legacy] ($M) ($M)
Pfizer Lyrica (pregabalin: $3,321M in FY2019, down 33.2% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2019
3,321
Period ended Dec 31, 2019
Change on a year earlier
-33.2%
4,970 in FY2018
History
4 years
Since FY2016
Sources
2
Documents cited below
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-27) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lyrica (pregabalin — Upjohn spin-off to Viatris Nov 2020) [legacy] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 3,321 | -33.2% | Form 10-K (filed 2020-02-27) ↗ |
| FY2018 | Dec 31, 2018 | 4,970 | -1.9% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 5,065 | +2.0% | Form 10-K (filed 2020-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 4,966 | – | Form 10-K (filed 2019-02-28) ↗ |
Cite this data
StockData. (2026). Pfizer Lyrica (pregabalin ($M), annual FY2016–FY2019 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/lyrica-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.